LSD therapy shows promise for major depression in Phase 3 trial, highlighting systemic gaps in mental health care
Original framing: “STAT+: Definium LSD therapy helped patients with major depression in late-stage trial” — STAT News
The Phase 3 trial provides evidence that LSD therapy may be effective for treating major depression, but it does not establish long-term safety or efficacy. Scientific research must also consider the mechanisms by which psychedelics affect the brain and how these effects interact with social and environmental factors.
The Phase 3 trial of LSD therapy for major depression reveals both the potential and the limitations of a biomedical approach to mental health.
While the results are promising, they must be contextualized within a broader systemic analysis that includes historical patterns of drug regulation, cross-cultural perspectives on healing, and the structural determinants of mental health. Indigenous knowledge systems offer a valuable counterpoint to the clinical trial model, emphasizing community-based, holistic approaches. To move forward, psychedelic therapy must be integrated into a larger framework that addresses social determinants, ensures equitable access, and respects the cultural and spiritual dimensions of healing. This requires collaboration across disciplines, cultures, and sectors to build a more inclusive and effective mental health care system.